Inclusion Criteria:  confirmed arterial hypertension (1-3 antihypertensive drugs without any dosage change in the preceding 4 weeks) and average systolic/diastolic BP between >130/70 and ≤170/110 mmHg in 24h ambulatory blood pressure measurement (ABPM) HFpEF (defined by clinical signs and/or symptoms of heart failure, objective structural cardiac abnormalities according to the ESC criteria [1] , elevated NT-proBNP ≥125 pg/mL and left-ventricular ejection fraction ≥55%) NYHA-Class II or III Confirmation of an elevated cardiac filling pressures (LVEDP >= 16 mmHg and PCWP >= 15 mmHg at rest or >=25 mmHg during exercise) by catheterization Age 18-80 years Written informed consent  Exclusion Criteria:  ≥1 main renal artery diameter <3.0 mm main renal artery length < 20 mm a single functioning kidney presence of abnormal kidney tumors renal artery aneurysm pre-existing renal stent or history of renal artery angioplasty fibromuscular disease of the renal arteries presence of renal artery stenosis of any origin ≥50% iliac/femoral artery stenosis precluding femoral access for RDN fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial (participants using a hormone-based method have to be informed of possible effects of the trial device on contraception). participation in other interventional trials patients under legal supervision or guardianship suspected lack of compliance pregnant women Presence of intracardiac pacemakers or implantable cardioverter/defibrillators